Country for PR: Hong Kong
Contributor: PR Newswire Asia (Hong Kong)
Thursday, July 22 2021 - 17:58
AsiaNet
Synthetic Biology Startup Allozymes Raises US $5 Million Seed Round to Deliver Sustainable, Scalable Manufacturing of Natural Ingredients
SINGAPORE, July 22, 2021 /PRNewswire-AsiaNet/ --

-Responsible consumers and companies are increasingly unwilling to tolerate the 
significant environmental impacts associated with natural ingredients sourcing. 
-The startup, co-founded by scientist-entrepreneurs, Peyman Salehian, PhD and 
Akbar Vahidi, PhD, employs a unique technology platform for the sustainable and 
scalable synthesis of natural ingredients.  
-Xora Innovation, the deep science investment platform of Temasek Holdings, 
leads the round with participation from SOSV, TI Platform Management, and 
Entrepreneur First.

Allozymes(https://www.allozymes.com/), a Singapore-based, synthetic biology 
startup, announced today that it has raised US $5 million in a seed financing 
round led by Xora Innovation, the deep science investment arm of Temasek 
Holdings. SOSV, TI Platform Management, and Entrepreneur First have also joined 
the round. 

Co-founded by scientist-entrepreneurs Peyman Salehian, PhD and Akbar Vahidi, 
PhD, Allozymes plans to disrupt the trillion dollar biomanufacturing sector by 
delivering cleaner, greener, sustainably-produced natural ingredients, at 
scale, through custom-designed enzymes. 

"Think of enzymes as autonomous nano-scale bio-machines that build molecules or 
break them down as needed, to provide energy, weaponry and construction 
material for living cells. It takes millions of years for nature to evolve 
these bio-machines for natural processes like the creation of cheese and wine 
but at Allozymes we accelerate the evolution of these bio-machines and engineer 
them in a matter of weeks," said Dr. Akbar Vahidi, CTO of Allozymes.

Enzyme engineering is all about finding the right enzyme from a large number of 
enzyme variants. Much like searching for a needle in a haystack, this process 
has been a major bottleneck for the development of specialty industrial 
enzymes. Accordingly, current enzyme engineering processes remain 
time-consuming and costly, discouraging wider industrial adoption.

Allozymes' proprietary platform analyzes and maps millions of enzyme variants 
per day, boosting the likelihood of developing the most effective, 
fit-for-purpose enzyme for a given commercial application. Allozymes has 
already demonstrated the ability of their platform to produce novel functional 
enzymes through pilot projects with innovative pharma, agri-food, and personal 
care companies, in a fraction of the time and cost, compared to robotics 
technology. These enzymes include oxidases, reductases, isomerases, and 
hydrolases, workhouse enzymes of industrial biotechnology.

The platform is also capable of generating massive enzyme performance datasets, 
exponentially larger than competitors.

"We plan to utilize this data for enzyme discovery, design, and optimization. 
Ingredient manufacturers would only need to search in our data set to find the 
right enzymes for their needs or to quickly improve their available enzymes," 
said Dr. Peyman Salehian, CEO of Allozymes. "Our biotechnology platform enables 
the sustainable and economical production of natural ingredients for a broad 
array of industrial applications, everything from sweeteners, to natural 
colors, to vitamins, personal care and cosmetic ingredients, for a start." 

The company plans to use the proceeds of the seed financing to establish its 
Singapore-based manufacturing and business infrastructure and prioritize the 
strong demand it is seeing in the ASEAN and broader APAC region.

"Whether for food, fashion, fuels, or electronics, Allozymes enables commercial 
access to custom enzymes at unprecedented speed, scale and quality," said Donna 
See, CEO of Xora Innovation. "Embedded in the fastest-growing sustainable 
products market in the world, Allozymes is well-positioned with a unique value 
proposition for ESG-minded partners in the region and beyond."

Duncan Turner, General Partner of SOSV, said, "Engineered enzymes have only 
just skimmed the surface of their potential impact. Allozymes exponentially 
speeds up enzyme development, enabling engineered enzymes to become a 
foundational part of the future of agriculture, biofuels, CPGs, and chemical 
processing." 

About Allozymes

Founded in 2019, Allozymes(https://www.allozymes.com/) is delivering cleaner, 
greener, sustainably-produced natural ingredients, at scale. Through the power 
of custom enzymes, we help our partners achieve their objectives for 
environmentally-responsible biomanufacturing across a wide range of 
applications, including agri-food, biofuels, pharma, and more. For more 
information, please visit www.allozymes.com.

SOURCE:  Allozymes
Translations

Japanese